APA

Gnant M., Pfeiler G., Steger G. G., Egle D., Greil R., Fitzal F., Wette V., Balic M., Haslbauer F., Melbinger-Zeinitzer E., Bjelic-Radisic V., Jakesz R., Marth C., Sevelda P., Mlineritsch B., Exner R., Fesl C., Frantal S. & Singer C. F. (20200615). Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. : The Lancet. Oncology.

Chicago

Gnant Michael, Pfeiler Georg, Steger Günther G, Egle Daniel, Greil Richard, Fitzal Florian, Wette Viktor, Balic Marija, Haslbauer Ferdinand, Melbinger-Zeinitzer Elisabeth, Bjelic-Radisic Vesna, Jakesz Raimund, Marth Christian, Sevelda Paul, Mlineritsch Brigitte, Exner Ruth, Fesl Christian, Frantal Sophie and Singer Christian F. 20200615. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. : The Lancet. Oncology.

Harvard

Gnant M., Pfeiler G., Steger G. G., Egle D., Greil R., Fitzal F., Wette V., Balic M., Haslbauer F., Melbinger-Zeinitzer E., Bjelic-Radisic V., Jakesz R., Marth C., Sevelda P., Mlineritsch B., Exner R., Fesl C., Frantal S. and Singer C. F. (20200615). Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. : The Lancet. Oncology.

MLA

Gnant Michael, Pfeiler Georg, Steger Günther G, Egle Daniel, Greil Richard, Fitzal Florian, Wette Viktor, Balic Marija, Haslbauer Ferdinand, Melbinger-Zeinitzer Elisabeth, Bjelic-Radisic Vesna, Jakesz Raimund, Marth Christian, Sevelda Paul, Mlineritsch Brigitte, Exner Ruth, Fesl Christian, Frantal Sophie and Singer Christian F. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. : The Lancet. Oncology. 20200615.